EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM

Frances M Bashore iD, Vittorio L Katis iD, Yuhong Du, Arunima Sikdar iD, Dongxue Wang, William J Bradshaw iD, Karolina A Rygiel, Tina M Leisner, Rod Chalk, Swati Mishra, C Andrew Williams iD, Opher Gileadi und 10 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0293548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Frances M Bashore und 21 weiteren Autor:innen. Beteiligte Einrichtung: Structural Genomics Consortium, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina a…. Hauptthemen laut MEDLINE: src Homology Domains, Protein-Tyrosine Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA sequencing and genetic data support spleen tyrosine kinase (SYK) and high affinity immunoglobulin epsilon receptor subunit gamma (FCER1G) as putative targets to be modulated for Alzheimer’s disease (AD) therapy. FCER1G is a component of Fc receptor complexes that contain an immunoreceptor tyrosine-based activation motif (ITAM). SYK interacts with the Fc receptor by binding to doubly phosphorylated ITAM (p-ITAM) via its two tandem SH2 domains (SYK-tSH2). Interaction of the FCER1G p-ITAM with SYK-tSH2 enables SYK activation via phosphorylation. Since SYK activation is reported to exacerbate AD pathology, we hypothesized that disruption of this interaction would be beneficial for AD patients. Herein, we developed biochemical and biophysical assays to enable the discovery of small molecules that perturb the interaction between the FCER1G p-ITAM and SYK-tSH2. We identified two distinct chemotypes using a high-throughput screen (HTS) and orthogonally assessed their binding. Both chemotypes covalently modify SYK-tSH2 and inhibit its interaction with FCER1G p-ITAM, however, these compounds lack selectivity and this limits their utility as chemical tools.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

src Homology DomainsProtein-Tyrosine KinasesHumansImmunoreceptor Tyrosine-Based Activation MotifIntracellular Signaling Peptides and ProteinsSyk KinasePhosphorylationReceptors, FcEnzyme Precursors

Substanzen

Protein-Tyrosine KinasesIntracellular Signaling Peptides and ProteinsSyk KinaseReceptors, FcEnzyme PrecursorsSYK protein, human

Autor:innen und Institutionen

  • Structural Genomics Consortium, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
  • Nuffield Department of Medicine, Centre for Medicines Discovery, ARUK Oxford Drug Discovery Institute, University of Oxford, Headington, Oxford, United Kingdom.
  • Department of Pharmacology and Chemical Biology, School of Medicine, Emory University, Atlanta, GA, United States of America.
  • Emory Chemical Biology Discovery Center, School of Medicine, Emory University, Atlanta, GA, United States of America.
  • Division of Chemical Biology and Medicinal Chemistry, Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United Sta…
  • Department of Laboratory Medicine and Pathology, School of Medicine, University of Washington, Seattle, WA, United States of America.

ORCID-Profile: Frances M Bashore, Vittorio L Katis, Arunima Sikdar, William J Bradshaw, C Andrew Williams, Gregory W Carter, Alison D Axtman

Förderung

  • NCI NIH HHS
  • NIA NIH HHS
  • National Institute on Aging
  • Bayer Pharma AG
  • Boehringer Ingelheim
  • Canada Foundation for Innovation
  • Eshelman Institute for Innovation, University of North Carolina at Chapel Hill
  • Genome Canada

Zitieren

APA

Bashore, F. M., Katis, V. L., Du, Y., Sikdar, A., Wang, D., Bradshaw, W. J., Rygiel, K. A., Leisner, T. M., Chalk, R., Mishra, S., Williams, C. A., Gileadi, O., Brennan, P. E., Wiley, J. C., Gockley, J., Cary, G. A., Carter, G. W., Young, J. E., Pearce, K. H., …, & Axtman, A. D. (2024). Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM. PLOS ONE. https://doi.org/10.1371/journal.pone.0293548

Vancouver

Bashore FM, Katis VL, Du Y, Sikdar A, Wang D, Bradshaw WJ, et al. Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM. PLOS ONE. 2024. doi:10.1371/journal.pone.0293548

BibTeX
@article{Bashore2024,
  author = {Bashore, Frances M and Katis, Vittorio L and Du, Yuhong and Sikdar, Arunima and Wang, Dongxue and Bradshaw, William J and Rygiel, Karolina A and Leisner, Tina M and Chalk, Rod and Mishra, Swati and Williams, C Andrew and Gileadi, Opher and Brennan, Paul E and Wiley, Jesse C and Gockley, Jake and Cary, Gregory A and Carter, Gregory W and Young, Jessica E and Pearce, Kenneth H and Fu, Haian and Emory-Sage-SGC TREAT-AD Center, Emory-Sage-SGC TREAT-AD Center and Axtman, Alison D},
  title = {Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0293548}
}
Kostenlos starten →